Journal Mobile Options
Table of Contents
Vol. 221, No. 2, 2010
Issue release date: August 2010

Two Congenital Cases of Pigmented Epithelioid Melanocytoma Studied by Fluorescent in situ Hybridization for Melanocytic Tumors: Case Reports and Review of These Recent Topics

Battistella M. · Prochazkova-Carlotti M. · Berrebi D. · Bennaceur S. · Edan C. · Riffaud L. · Rütten A. · Fraitag S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The term ‘pigmented epithelioid melanocytoma’ (PEM) has recently been proposed as a nosological framework grouping lesions formerly known as animal-type melanomas, sporadic epithelioid blue nevi and Carney complex-associated epithelioid blue nevi. Congenital PEMs have been reported extremely rarely and their prognosis is poorly known. Four-color fluorescent in situ hybridization (FISH) for melanocytic lesions is a recent method developed to assess the malignant potential of ambiguous melanocytic lesions. Here we describe 2 cases of congenital epithelioid and strongly pigmented melanocytic lesions consistent with PEM. No BRAF gene mutation was found in the 2 cases. FISH for melanocytic lesions was also performed. The first case proved entirely negative, whereas the second one showed a positive zone with an extra copy of chromosome 6. The prognosis and management of PEM are discussed, with a review of the available data on the history, demographics, molecular alterations and histopathological aspects of this entity. PEM seems to represent a unique low-grade melanocytic tumor with a limited potential of metastasis to lymph nodes, but a favorable long-term clinical course. The published data about FISH for melanocytic tumors, and especially PEM, are reviewed. Four-color FISH may be a useful tool to assess more accurately the prognosis of these tumors.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Zembowicz A, Carney JA, Mihm MC: Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 2004;28:31–40.
  2. Mandal RV, Murali R, Lundquist KF, et al: Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up. Am J Surg Pathol 2009;33:1778–1782.
  3. Iglesias C, Torrelo A, Colmenero I, et al: Isolated multiple congenital epithelioid blue naevus. Br J Dermatol 2005;152:391–393.
  4. Martinez-Barba E, Polo-Garcia LA, Ferri-Niguez B, et al: Congenital giant melanocytic nevus with pigmented epithelioid cells: a variant of epithelioid blue nevus. Am J Dermatopathol 2002;24:30–35.
  5. Richardson SK, Tannous ZS, Mihm MC Jr: Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 2002;47:77–90.
  6. Gerami P, Jewell SS, Morrison LE, et al: Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146–1156.
  7. Morey AL, Murali R, McCarthy SW, et al: Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology 2009;41:383–387.
  8. Carney JA, Ferreiro JA: The epithelioid blue nevus: a multicentric familial tumor with important associations, including cardiac myxoma and psammomatous melanotic schwannoma. Am J Surg Pathol 1996;20:259–272.
  9. Wilkes D, McDermott DA, Basson CT: Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol 2005;6:501–508.
  10. Atherton DJ, Pitcher DW, Wells RS, et al: A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome. Br J Dermatol 1980;103:421–429.
  11. Koopman RJ, Happle R: Autosomal dominant transmission of the NAME syndrome (nevi, atrial myxoma, mucinosis of the skin and endocrine overactivity). Hum Genet 1991;86:300–304.
  12. Rhodes AR, Silverman RA, Harrist TJ, et al: Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: the ‘LAMB’ syndrome. J Am Acad Dermatol 1984;10:72–82.
  13. Carney JA, Gordon H, Carpenter PC, et al: The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985;64:270–283.
  14. Veugelers M, Wilkes D, Burton K, et al: Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci USA 2004;101:14222–14227.
  15. Bossis I, Voutetakis A, Matyakhina L, et al: A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004;41:596–600.
  16. Kirschner LS, Carney JA, Pack SD, et al: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89–92.
  17. Casey M, Vaughan CJ, He J, et al: Mutations in the protein kinase A R1α regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 2000;106:R31–R38.
  18. Groben PA, Harvell JD, White WL: Epithelioid blue nevus: neoplasm Sui generis or variation on a theme? Am J Dermatopathol 2000;22:473–488.
  19. Izquierdo MJ, Pastor MA, Carrasco L, et al: Epithelioid blue naevus of the genital mucosa: report of four cases. Br J Dermatol 2001;145:496–501.
  20. Moreno C, Requena L, Kutzner H, et al: Epithelioid blue nevus: a rare variant of blue nevus not always associated with the Carney complex. J Cutan Pathol 2000;27:218–223.
  21. Naylor EM, Ruben BS, Robinson-Bostom L, et al: Subungual blue nevus with combined phenotypic features. J Am Acad Dermatol 2008;58:1021–1024.
  22. O’Grady TC, Barr RJ, Billman G, et al: Epithelioid blue nevus occurring in children with no evidence of Carney complex. Am J Dermatopathol 1999;21:483–486.
  23. Pinto A, Raghavendra S, Lee R, et al: Epithelioid blue nevus of the oral mucosa: a rare histologic variant. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:429–436.
  24. Zembowicz A, Mihm MC: Dermal dendritic melanocytic proliferations: an update. Histopathology 2004;45:433–451.
  25. Dick W: Melanosis in men and horses. Lancet 1832;ii:192.

    External Resources

  26. Levene A: Equine melanotic disease. Tumori 1971;57:133–168.
  27. Darier J: Le mélanome malin mésenchymateux ou mélanosarcome. Bull Assoc Fr Etud Cancer 1925;14:221–249.
  28. Carleton A, Biggs R: Diffuse mesodermal pigmentation with congenital cranial abnormality. Br J Dermatol Syph 1948;60:10–13.
  29. Levene A: Disseminated dermal melanocytosis terminating in melanoma: a human condition resembling equine melanotic disease. Br J Dermatol 1979;101:197–205.
  30. Levene A: On the natural history and comparative pathology of the blue naevus. Ann R Coll Surg Engl 1980;62:327–334.
  31. Antony FC, Sanclemente G, Shaikh H, et al: Pigment-synthesizing melanoma (so-called animal-type melanoma): a clinicopathological study of 14 cases of a poorly known distinctive variant of melanoma. Histopathology 2006;48:754–762.
  32. Cecchi R, Rapicano V: Pigment-synthesizing (animal-type) melanoma with satellite metastasis. Eur J Dermatol 2007;17:335–336.
  33. Crowson AN, Magro CM, Mihm MC Jr: Malignant melanoma with prominent pigment synthesis: ‘animal-type’ melanoma – a clinical and histological study of six cases with a consideration of other melanocytic neoplasms with prominent pigment synthesis. Hum Pathol 1999;30:543–550.
  34. Kazakov DV, Rutten A, Kempf W, et al: Melanoma with prominent pigment synthesis (animal-type melanoma): a case report with ultrastructural studies. Am J Dermatopathol 2004;26:290–297.
  35. Ludgate MW, Fullen DR, Lee J, et al: Animal-type melanoma: a clinical and histopathological study of 22 cases from a single institution. Br J Dermatol 2010;162:129–136.
  36. Orlandi A, Costantini S, Campione E, et al: Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase π. Arch Dermatol 2009;145:55–62.
  37. Punjabi S, Wright C, Teixeira F, et al: Intraepidermal animal-type melanoma. Int J Dermatol 2006;45:957–959.
  38. Requena L, de la Cruz A, Moreno C, et al: Animal-type melanoma: a report of a case with balloon-cell change and sentinel lymph node metastasis. Am J Dermatopathol 2001;23:341–346.
  39. Sass U, Kolivras A, Andre J: Malignant ‘animal-type’ melanoma in a seropositive African man. J Am Acad Dermatol 2006;54:547–548.
  40. Vezzoni GM, Martini L, Ricci C: A case of animal-type melanoma (or pigmented epithelioid melanocytoma?): an open prognosis. Dermatol Surg 2008;34:105–109.
  41. Zembowicz A, Knoepp SM, Bei T, et al: Loss of expression of protein kinase A regulatory subunit 1α in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol 2007;31:1764–1775.
  42. Howard B, Ragsdale B, Lundquist K: Pigmented epithelioid melanocytoma: two case reports. Dermatol Online J 2005;11:1.

    External Resources

  43. Ito K, Mihm MC: Pigmented epithelioid melanocytoma: report of first Japanese cases previously diagnosed as cellular blue nevus. J Cutan Pathol 2009;36:439–443.
  44. Ward JR, Brady SP, Tada H, et al: Pigmented epithelioid melanocytoma. Int J Dermatol 2006;45:1403–1405.
  45. Scolyer RA, Thompson JF, Warnke K, et al: Pigmented epithelioid melanocytoma. Am J Surg Pathol 2004;28:1114–1115, author reply 1115–1116.
  46. Fraitag S, Vignon-Pennamen MD: Spitz tumor and pigmented epithelioid melanocytoma: new nosological frameworks for commonly ill-defined tumors (in French). Ann Dermatol Venereol 2009;136:133–144.
  47. Magro CM, Crowson AN, Mihm MC Jr, et al: The dermal-based borderline melanocytic tumor: a categorical approach. J Am Acad Dermatol 2010;62:469–479.
  48. Murali R, McCarthy SW, Scolyer RA: Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv Anat Pathol 2009;16:365–382.
  49. Kutzner H, Schärer L, Requena L: Epithelioid and hyperpigmented melanocytic tumors: an overview (in German). Pathologe 2007;28:411–421.
  50. Barnhill RL, Cerroni L, Cook M, et al: State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol 2010;17:73–90.
  51. White S, Chen S: What is ‘pigmented epithelioid melanocytoma’? Am J Surg Pathol 2005;29:1118, author reply 1118–1119.
  52. Milette F: Pigmented epithelioid melanocytoma: report of first Japanese cases previously diagnosed as cellular blue nevus. J Cutan Pathol 2009;36:1027–1028.
  53. Milette F, Ackerman A: ‘Animal-Type Melanoma’ and ‘Entities’ Related to It. Exegesis of a Subject until Now Incomprehensible. New York, Ardor Scribendi, 2006.
  54. Busam KJ, Murali R, Pulitzer M, et al: Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol 2009;33:1386–1395.
  55. Paradela S, Fonseca E, Pita S, et al: Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol 2009;36:740–752.
  56. Platz A, Egyhazi S, Ringborg U, et al: Human cutaneous melanoma: a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1:395–405.
  57. Blokx WA, van Dijk MC, Ruiter DJ: Molecular cytogenetics of cutaneous melanocytic lesions: diagnostic, prognostic and therapeutic aspects. Histopathology 2010;56:121–132.
  58. Bastian BC, LeBoit PE, Hamm H, et al: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170–2175.
  59. Bastian BC, Wesselmann U, Pinkel D, et al: Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 1999;113:1065–1069.
  60. Newman MD, Lertsburapa T, Mirzabeigi M, et al: Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod Pathol 2009;22:989–995.
  61. Newman MD, Mirzabeigi M, Gerami P: Chromosomal copy number changes supporting the classification of lentiginous junctional melanoma of the elderly as a subtype of melanoma. Mod Pathol 2009;22:1258–1262.
  62. Busam KJ, Fang Y, Jhanwar SC, et al: Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization. J Cutan Pathol 2010;37:196–203.
  63. Pouryazdanparast P, Newman M, Mafee M, et al: Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol 2009;33:1396–1400.
  64. Dalton SR, Gerami P, Kolaitis NA, et al: Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol 2010;34:231–237.
  65. McCalmont TH: Gone FISHing. J Cutan Pathol 2010;37:193–195.
  66. Isaac AK, Lertsburapa T, Pathria Mundi J, et al: Polyploidy in Spitz nevi: a not uncommon karyotypic abnormality identifiable by fluorescence in situ hybridization. Am J Dermatopathol 2010;32:144–148.
  67. Vergier B, Prochazkova-Carlotti M, de la Fouchardière A, et al: Intérêt de la FISH dans le diagnostic et le pronostic des tumeurs mélaniques ambiguës: étude européenne sur 113 patients (abstract). Ann Pathol 2009;29S:S136–S138.
  68. Bastian BC, Xiong J, Frieden IJ, et al: Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 2002;161:1163–1169.
  69. Mateus C, Palangie A, Franck N, et al: Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol 2008;59:801–810.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50